In Brief
In tumors with high PI3K pathway activity, such as triple-negative breast cancer (TNBC), selective inhibitors of PI3K/AKT/ mTOR pathway kinases exhibit limited efficacy as single agents. To identify possible co-targeting opportunities, we systematically analyzed responses to a compendium of PI3K/AKT/mTOR inhibitors with varying degrees of polyselectivity. We found that preclinical drugs that inhibit both mTOR and other PI3K-like kinases are more potent and effective than most clinical-grade PI3K pathway inhibitors. These polyselective mTOR inhibitors warrant further investigation as a new strategy for targeting TNBC.
INTRODUCTION
Triple-negative breast cancers (TNBCs) are high-grade, invasive mammary ductal carcinomas defined by the absence of estrogen and progesterone receptor expression and HER2-amplification (Foulkes et al., 2010) . TNBCs are managed primarily with chemotherapy, but early disease relapse and poor overall survival underscore the need for new treatments (Foulkes et al., 2010) . TNBCs have the highest inferred phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling activity of all breast cancer subtypes, providing a rationale for the use of PI3K pathway inhibitors (Cancer Genome Atlas Network, 2012) . High PI3K pathway activity in TNBC results both from activating mutations in PIK3CA, which encodes the catalytic subunit of a phosphoinositide kinase, and reduced expression of PTEN and INPP4B, which encode phosphoinositide phosphatases (Cancer Genome Atlas Network, 2012) . PI3K pathway kinases have been targeted with >40 small-molecule drugs but clinical responses to date have been modest (Janku et al., 2018) . PI3K pathway drugs are non-selective for transformed cells, which also limits their therapeutic index (Chia et al., 2015) . Isoform-selective PI3K inhibitors are better tolerated but only sporadically active in solid tumors, possibly due to insufficient pathway inhibition or feedback mechanisms that cause pathway reactivation (Elkabets et al., 2013; Schwartz et al., 2015) .
One way to overcome such limitations is to combine PI3K pathway inhibitors with other drugs or exploit the polyselectivity of existing molecules (André et al., 2019; Knight et al., 2010) . Whereas many PI3K pathway drugs inhibit several PI3K isoforms and/or mTOR, some also inhibit other PI3K-like kinases (PIKKs) because of structurally similar ATP binding sites. For example, the PI3K-mTOR inhibitor dactolisib (NVP-BEZ235) and the active-site mTOR inhibitors Torin1 and Torin2, which antagonize the activities of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), also inhibit ataxia telangiectasia and Rad3-related (ATR), ataxia telangiectasia mutated (ATM), and/or DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) (Liu et al., 2010 (Liu et al., , 2013 Toledo et al., 2011) . This unique polyselectivity may be particularly relevant to TNBC because of frequent alterations in TP53, MYC, and CCNE1, which cause increased dependency on PIKKs due to defective DNA damage checkpoints and increased replication stress (Cancer Genome Atlas Network, 2012; Lin et al., 2017; Zeman and Cimprich, 2014) .
In this paper, we analyzed the responses of TNBC cells with an activated PI3K pathway to a diverse collection of PI3K pathway inhibitors. We found that most drugs neither fully block proliferation nor cause cell death. In contrast, the preclinical compound Torin2 induced apoptosis in all cell lines tested. To determine which of the four high-affinity targets of Torin2 is responsible, we used a chemical genetic approach involving dose-response studies in multiple cell lines, analysis of chemical analogs, and pharmacological reconstitution with mixtures of selective inhibitors. Phenotypes were determined using single-cell, time course, and pulse-labeling assays. These studies show that inhibition of both mTOR and other PIKKs is responsible for the high activity of Torin2 in TNBC. Thus, co-targeting several PIKKs with a single polyselective drug or a mixture of selective compounds makes it possible to exploit replicative and checkpoint vulnerabilities unique to TNBCs to promote selective cell killing.
RESULTS

Torin2 Produces Strong Cytotoxic and Anti-proliferative Effects in TNBC Cells
Breast cancer cell lines are classified as basal or luminal based on gene expression (Neve et al., 2006) . We performed western blotting on 46 cell lines and found that those with basal-like gene expression had uniformly low levels of PTEN and/or INPP4B (Figure S1A; Table S1 ); five such lines were selected for compound screening (HCC1806, Hs 578T, HCC38, BT-549, and HCC70). A sixth basal line (BT-20) with an activating PIK3CA mutation (H1047R) but normal levels of PTEN and INPP4B was also screened. All six lines lack hormone receptor expression and HER2 amplification and are homozygous for TP53 mutations (Table S2) . We assembled a diverse panel of 23 PI3K pathway inhibitors that included clinically approved drugs, investigational agents, and tool compounds; the MEK inhibitor trametinib served as a mitogen-activated protein kinase (MAPK)-pathway-specific comparator ( Figure 1A ; Table S3 ). Sub-confluent cultures were treated for 72 h with each drug at nine doses and viable cells counted by microscopy at time t = 0 and 72 h ( Figure S1B ). Dose-response data were analyzed using growth rate inhibition (GR) metrics, which quantify drug sensitivity while correcting for differences in cell division times (T d ) (Hafner et al., 2016) : GR 50 is analogous to the half maximal inhibitory concentration (IC 50 ) and measures potency, while GR max is analogous to the maximal drug effect (E max ) and measures efficacy ( Figure S1C ). A value of GR max < 0 indicates a net cell loss, a value of zero represents no change in viable cell number, and a value > 0 indicates a net cell gain. By convention, GR max = 1 in control cultures, which were treated with DMSO only. Highly effective responses (i.e., negative GR max values) were rare across the 144 drug-cell line combinations examined (Figure 1B) , but three drugs were broadly cytotoxic: the phase 3 PI3K p110 pan-isoform inhibitor buparlisib, the phase 1 PI3K-mTOR inhibitor omipalisib, and the preclinical mTOR-PIKK inhibitor Torin2. Omipalisib and Torin2 were also highly potent, with nanomolar GR 50 values ( Figure S1D ). Torin2 is the least studied molecule of the three, but we found it to be more cytotoxic in 19 basal-like cell lines than sapanisertib, an active-site mTOR inhibitor presently in clinical trials ( Figure 1C ). Torin2 exhibited similar efficacy to sapanisertib in luminal breast cancer cell lines (n = 7) and caused little or no cytotoxicity in non-malignant mammary epithelial cells (n = 2) ( Figure S1E ). Thus, Torin2 may represent an improved way to target TNBC.
To identify factors influencing drug response, we assayed proliferation and apoptosis in live cells. To enable a principled comparison, compounds were used at the lowest concentration eliciting a GR max response (i.e., the ''GR max dose''). We imaged HCC1806 cells expressing a nuclear localization sequence fused to mCherry (NLS-mCherry) continuously for >5 days ($4.5 cell divisions; T d = 28 h) in the presence of DMSO or several drugs whose GR max values span a broad range. Drugs with positive GR max values, such as the PI3Ka inhibitor alpelisib (GR max = 0.92), the active-site mTOR inhibitor AZD8055 (GR max = 0.56), and the PI3K-mTOR inhibitor apitolisib (GR max = 0.37), reduced viable cell number but did not fully block proliferation ( Figure 1D ). Conversely, drugs with negative GR max values such as Torin2 (GR max = À0.16) and omipalisib (GR max = À0.29) steadily reduced cell number. At a 10-fold lower dose (0.32 mM) of Torin2 or omipalisib, there was still no increase in cell number over time, consistent with complete cytostasis or a balance between cell division and death ( Figure S1F ).
As another measure of proliferation, we exposed HCC1806 cells to drugs for 24 h and then added (2 0 S)-2 0 -deoxy-2 0 -fluoro-5-ethynyluridine (F-ara-EdU), a non-toxic thymidine analog that is incorporated into newly synthesized DNA, for an additional 75 h (2.7 3 T d ) (Neef and Luedtke, 2011) . GR max doses of alpelisib, AZD8055, and apitolisib were only partly effective at inhibiting F-ara-EdU labeling, resulting in 0.7%, 6.3%, and 65.4% unlabeled cells; in contrast, Torin2 and omipalisib each inhibited the labeling of >99% of viable cells (Figures 1E and S1G) . Thus, the low GR max values of Torin2 and omipalisib are associated with fewer cells that actively synthesize DNA during drug exposure.
To assay apoptosis, we exposed six cell lines to drugs in the presence of a fluorogenic substrate of executioner caspases 3 and 7 (C3 and C7) and measured substrate cleavage by imaging ( Figure S1H ). We then calculated the fold change in the area under the fluorescence curve (AUC) between 0 and 72 h relative to a DMSO control ( Figures 1F and 1G ). Drugs such as AZD8055 induced no detectable C3 and/or C7 activity in any cell line. In contrast, Torin2 and omipalisib increased C3 and/or C7 activity (C) GR max , GR 50 values in 19 TNBC cell lines. **p < 0.01, ***p < 0.001, and n.s. (G) C3 and/or C7 activity (i.e., mean fold change in AUC ± SEM for drug versus DMSO); n = 2 experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA and Tukey's test (selected comparisons shown). Drugs were used at GR max doses (1-3.2 mM) in (D)-(G), with exceptions as noted in STAR Methods. See also Figure S1 and Tables S1-S3 . by an average of $3.5-fold across all six lines. Overall, these data show that low GR max values for Torin2 and omipalisib in TNBC cells result from effective inhibition of proliferation and induction of apoptosis.
PI3K/AKT/mTOR Inhibitors Impede Progression of S Phase
To evaluate the effects of Torin2 on signaling, we exposed TNBC cells to GR max doses of drugs for 24 h and then quantified the levels or localization of nine proteins or phosphoproteins by immunofluorescence microscopy ( Figures 1A, 2A , and S2A-S2C). AKT activity was inferred from (1) phosphorylation at T308 and S473, (2) phosphorylation of GSK-3b at S9, and (3) nuclear localization of FoxO3. The activities of mTORC1, mTORC2, and S6K1 were assayed by phospho-4E-BP1 T37 and/or T46, phospho-AKT S473, and phospho-S6 S235 and/or S236. We also measured levels of cyclin D1, p21, and p27, which are regulated by the PI3K pathway. Based on changes in these proteins/ phosphoproteins, Torin2 and omipalisib were found to be the most effective PI3K pathway inhibitors (Figures 2A and S2D ).
To assay the ''output'' of the PI3K pathway, we quantified CDK-dependent phosphorylation of retinoblastoma protein (p-pRb) on S807 and/or S811. When mitogenic signaling is low, CDK activity is also low, pRb is dephosphorylated, and E2F is inhibited, causing G1 arrest (Duronio and Xiong, 2013) . In HCC1806 cells, exposure to Torin2 or omipalisib for t = T d increased the percentage of p-pRb-low cells from 5% to 64% and 81%, compared to 6%-42% for six other PI3K pathway drugs ( Figures 2B and S2E ). Thus, low GR max values for Torin2 and omipalisib correlate with greater suppression of PI3K signaling and lower levels of p-pRb (Liang and Slingerland, 2003) .
To determine if Torin2 inhibits cell-cycle progression at the G1-to-S phase transition to a greater extent than other PI3K pathway drugs, we stained DNA with Hoechst and pulse-labeled S-phase cells with EdU ( Figure S3A ). Cell lines with different T d s were compared by exposing cells to drugs for t = T d and then labeling with EdU for 0.025 3 T d (40-70 min). EdU-positive cells were scored as being in S phase and EdU-negative cells scored as being in G0 or G1 (G0-G1) or G2 or mitosis (G2-M) based on DNA content. EdU-negative cells with a DNA content intermediate between G0-G1 and G2-M cells were scored as S-phasenon-replicating (S NR ) cells (Shi et al., 2001) .
Exposure of BT-20 cells to 0.3 3 GR max dose (1 mM) of Torin2 or omipalisib for t = T d (48 h) increased the G0-G1 fraction to $85% (from 55% in DMSO control) and reduced the S-phase fraction to 0% (from 33% in DMSO control; Figure 2C ). In contrast, GR max doses of drugs less effective than Torin2 at suppressing PI3K pathway activity (i.e., alpelisib and rapamycin) increased the G0-G1 fraction to a lesser degree (76%-79%) and incompletely reduced the S-phase fraction (to 13%-15%). Thus, in PIK3CA-mutant TNBC cells, the high activities of Torin2 and omipalisib are associated with an increased blockade of cells in G0-G1 and elimination of S-phase cells.
In contrast, exposure of other cell lines to Torin2 or omipalisib, even at doses that blocked proliferation, did not eliminate S-phase cells ( Figures 2C and S3B ). For example, 26%-41% of HCC70 cells were in S phase after exposure to Torin2 or omipalisib for t = T d (45 h). To determine if this phenotype arises because Torin2 and other PI3K pathway drugs impede progression of cells through S phase, we quantified the amount of EdU incorporated into DNA during pulse labeling. To identify S-phase cells independent of DNA synthesis, we measured levels of expression of the anaphase-promoting complex/cyclosomeCdh1 (APC) substrates geminin and cyclin A2 by immunofluorescence. In HCC70 cells, multiple PI3K pathway drugs reduced EdU content in geminin-and cyclin A2-positive cells (Figures 2D and 2E) . Torin2 suppressed DNA synthesis to the greatest degree and caused accumulation of S NR cells ($9% of all cells). In HCC1806 cells, Torin2 elicited even stronger inhibition of S phase, with accumulation of >20% of S NR cells ( Figures 2D,  2E , S3C, and S3D). These S NR cells exhibited decreased levels of geminin, cyclin A2, and p-pRb, consistent with cell-cycle exit ( Figures 2D and S3E ). PI3K pathway drugs also reduced EdU content in BT-549 and Hs 578T cells, with Torin2 again having the strongest effect ( Figures 2E, S3F , and S3G). The same was true for BT-20 cells exposed to drugs for a less time (t = 0.125À0.3 3 T d ; 6-14 h), substantially earlier than the G0-G1 arrest that occurred by t = T d ( Figures S3H and S3I) . Thus, Torin2 and other PI3K pathway drugs not only inhibit the cell cycle at the G1-to-S phase transition but also interfere with progression of S phase.
The PI3K pathway is known to play a role in nucleotide metabolism (Wang et al., 2009) . We therefore hypothesized that exposure of TNBC cells to PI3K pathway drugs impedes S phase by decreasing levels of DNA precursors (Juvekar et al., 2016) . To test this idea, we performed targeted metabolomic profiling by mass spectrometry following a short exposure of BT-549 cells to one of three mTOR inhibitors (rapamycin, AZD8055, or Torin2) or DMSO for t = 0.15 3 T d (6 h). Drug-exposed cells exhibited changes in levels of multiple purine and pyrimidine deoxyribonucleotides and their precursors, consistent with inhibition of both de novo synthesis and salvage pathways ( Figure 2F ; Table S4 ). Torin2 elicited the largest number of changes, but all three drugs elicited higher levels of cytidine and cytosine, key substrates in the salvage of pyrimidines. The drugs also increased levels of deoxythymidine monophosphate (dTMP) and decreased levels of deoxythymidine diphosphate (dTDP), consistent with reduced Table S4. activity of deoxythymidylate kinase, an enzyme that acts downstream of both de novo pyrimidine synthesis and salvage pathways. Thus, it is likely that Torin2 and the other drugs we tested inhibit S-phase progression at least in part by depleting TNBC cells of nucleotides required for DNA replication.
Torin2 Causes Substantial Cell Killing during S-G2 Phases To better understand how Torin2 acts on cells in different cell-cycle stages, we performed time-lapse imaging of asynchronous HCC1806 cells stably expressing H2B-mTurquoise and mVenus-hGeminin(1-110) (Sakaue-Sawano et al., 2008) . Cells were exposed to DMSO or 0.3 3 GR max dose (1 mM) of omipalisib or Torin2 and then followed for 48 h (n = 340 single cells tracked and analyzed, Figure 3A ). H2B-mTurquoise was used to identify nuclei, monitor cell division, and score cell death by nuclear fragmentation. Cell-cycle stage was determined by the fluorescence intensity level of mVenus, which is low in G1 and high in S and G2 (S-G2). In the presence of DMSO, single cells divided every 24.2 ± 0.8 h, consistent with measured population doubling times, and only $6% died ( Figure 3A ). Exposure to omipalisib caused the death of 38% of cells (n = 43/112) and blocked progression of 55% (n = 61/112); the remainder of the cells were incompletely blocked ( Figures 3A and 3B ). Torin2 was more cytotoxic, killing 51% of cells (n = 62/122) and blocking progression of 43% (n = 53/122).
Confirming data obtained from fixed cells, live-cell imaging showed that Torin2 and omipalisib are active during both G1 and S-G2 phases of the cell cycle. In the presence of omipalisib, a similar numbers of cells died in S-G2 (44%; n = 19/43) as in G1 (56% of cells; n = 24/43) ( Figures 3A and 3B ). In contrast, 8-fold more cells exposed to Torin2 died in S-G2 (89% of cells, n = 55/ 62) than in G1 (11%, n = 7/62). Among surviving cells, Torin2 also imposed a stronger S-G2 block than omipalisib: 30% of blocked cells (n = 16/53) were in S-G2 after exposure to Torin2 compared to only 2% (n = 1/61) for omipalisib. The strong effects of Torin2 on S-G2 cells caused the sequence of events leading to G1 block or death to differ between the two drugs. For example, the majority of omipalisib-treated cells that died in G1 (66.7%, n = 16/24) or remained blocked there (65%, n = 39/60) were in S-G2 at the time of drug exposure; they then proceeded through mitosis to the following G1 where they either died or arrested (G1 ''class 2'' death or block, Figures 3C and 3D ). In contrast, G1 class 2 deaths (57.1%, n = 4/7) and block (40.5%, n = 15/37) were less frequent in the presence of Torin2 because the majority of cells in S-G2 at the time of initial drug exposure never reached mitosis. We conclude that both Torin2 and omipalisib are active on cells in G1 and S-G2 but that exposure to Torin2 causes substantially greater arrest and death of S-G2 cells than omipalisib.
Torin2 Causes Replication Catastrophe Impaired S-phase progression by nucleotide insufficiency or other genotoxic insults is a cardinal manifestation of ''replication stress' ' (Zeman and Cimprich, 2014) . Stalled replication forks cause accumulation of single-stranded DNA (ssDNA) because the activities of DNA polymerases and replicative helicases become uncoupled; excess ssDNA can then consume replication factors and cause DNA breakage and death by ''replication catastrophe' ' (Toledo et al., 2013) . To determine if exposure to Torin2 causes accumulation of ssDNA, HCC1806 cells were labeled with 5-bromo-2'-deoxyuridine (BrdU) for t = T d , treated with GR max doses of the drug for t = 0.2 3 T d (5 h), and immunostained with anti-BrdU antibodies under non-denaturing (''native'') conditions. Exposure to Torin2, but not to omipalisib or AZD8055, increased the fraction of cells with elevated ssDNA $8-fold ( Figure 4A , labeled red, and Figure 4C ) and mean nuclear BrdU intensity in gated S-phase cells $2-fold ( Figure 4B ). Similar increases were observed with AZ20 and rabusertib, selective inhibitors of ATR and its substrate checkpoint kinase 1 (Chk1), which act together to stabilize stalled replication forks and suppress origin firing (Zeman and Cimprich, 2014) . Exposure of HCC1806 cells to Torin2, AZ20, and rabusertib also increased levels of phosphorylated H2A.X S139 (gH2A.X), a marker of DNA damage, and of the phosphorylated form of the ssDNAbinding protein RPA (p-RPA) modififed on S4 and/or S8 ( Figures  4A-4C ). Similar effects were seen in HCC70 cells but after longer periods of drug exposure ($0.5 3 T d , 24 h) (Figures S4A and S4B) . In HCC1806 cells, these responses were associated with activated intra-S-phase checkpoint signaling, as evidenced by a $15-fold increase in the fraction of cells with elevated phosphorylated Chk1 (p-Chk1) S317 and phosphorylated Chk2 (p-Chk2) T68 ( Figures 4C and S4C ). In contrast, neither AZD8055 nor omipalisib caused any detectable increase in ssDNA, gH2A.X, p-RPA, p-Chk1, or p-Chk2, despite inhibiting DNA synthesis. Thus, Torin2 is unique among the PI3K pathway drugs we tested in causing accumulation of ssDNA, DNA damage, and increased checkpoint signaling in TNBC cells.
To determine whether increased ssDNA and DNA damage precede accumulation of S NR cells and death, HCC1806 cells were exposed to Torin2 at 0.3 3 GR max dose (1 mM) for 0.2-1.7 3 T d (5-48 h). At 5, 11, 24, or 48 h, cells were pulse labeled with EdU for 0.025 3 T d (40 min) and counterstained with antigH2A.X antibodies. Between 5 and 48 h of drug exposure, $50%-60% of EdU-positive cells were positive for gH2A.X, a >10-fold increase over cells exposed to DMSO for 5 h ( Figure 4D ). Over the same time period, the fraction of EdU-negative cells that were gH2A.X-positive increased from 1% to 54%, these cells had DNA content values characteristic of S NR cells (Figure 4E) . Torin2 exposure was similar to rabusertib exposure in generating S NR cells with homogeneous, pan-nuclear gH2A.X staining, thereby demonstrating severe genotoxic stress and commitment to apoptosis (de Feraudy et al., 2010) (Figure 4F ). No such staining pattern was observed after cells were exposed to omipalisib. Overall, more than 50% of S-phase HCC1806 cells exposed to Torin2 for 5-48 h exhibited pan-nuclear gH2A.X staining, and similar effects were observed in other TNBC cell lines (Figures 4G and 4H) . Thus, ssDNA and DNA damage induced by Torin2 precede the appearance of S NR cells exhibiting hallmarks of replication catastrophe.
The Activity of Torin2 Results from Combined Inhibition of mTOR and Other PIKKs
To test the hypothesis that the activity of Torin2 on TNBC cells results from its unique polypharmacology, we attempted to reconstitute Torin2-induced phenotypes in HCC1806 and HCC70 cells by combining selective inhibitors of mTOR and other PIKKs. The combination of AZD8055 and rabusertib most closely matched the activity of Torin2 across a range of doses ( Figures 5A and S5A ), possibly because inhibition of Chk1 mimics the inhibition of both ATR and DNA-PKcs (Buisson et al., 2015) . AZD8055 combined with either rabusertib or AZ20 was more effective (by GR max ) than inhibiting mTOR alone and more potent (by GR 50 ) than inhibiting ATR or Chk1 alone. In a complementary approach, we compared AZD8055 to nine Torin2 analogs ( Figure S5B ) and Torin1, which inhibits mTORC1/2 and DNA-PK but not ATR or ATM (Liu et al., 2010) . Most Torin2 analogs were less potent than AZD8055 and Torin1 but were more effective (i.e., negative GR max values, Figures 5B and 5C).
To dissect the relative contribution of inhibiting mTOR or other PIKKs to the activity of Torin2 analogs, we exposed HCC1806 and HCC70 cells to a 100-fold concentration range of each drug for t = 0.33-0.5 3 T d (14 h) and assayed mTOR signaling activity by immunofluorescence microscopy of p-AKT S473 and p-4E-BP1 T37 and/or 46. We found that the magnitude of mTOR inhibition at 14 h correlated well with GR values at 72 h for multiple drugs and analogs, including Torin1 and AZD8055 ( Figures 5D and S5C , black regression lines). However, at low levels of mTOR signaling activity, the GR values for Torin2 (red circles), QL-VI-86 (#5), QL-V-107 (#6), QL-IV-100 (#7), and QL-VIII-58 (#8) were substantially lower, resulting in a discontinuous relationship between mTOR inhibition and GR values (Figures 5D and S5C, red lines or boxes). Thus, mTOR inhibition alone does not fully account for the high activity of these drugs. This same subset of drugs caused elevated pan-nuclear staining of gH2A.X in S-phase cells, consistent with inhibition of additional PIKKs (Figures 5D-5G and S5C-S5E). In HCC1806 cells, these drugs also elicited an increase in the fraction of p-pRblow cells in G1, S, and G2-M phases, indicative of arrest at multiple points in the cell cycle (Figures 5E, black lines beneath scatterplots, and 5F). We conclude that Torin2 and its analogs exhibit more or less of two distinct cellular activities. Whereas all compounds inhibit mTOR and cause growth inhibition, a subset of compounds including Torin2 also inhibit additional PIKKs to cause DNA damage and cytotoxicity. The most effective drugs are those with the strongest combined activity.
Combined Inhibition of mTOR and ATR or Chk1 Is Beneficial because Multiple Pathways Required for S Phase Are Co-targeted The high activity of Torin2 and its analogs is unexpected. In principle, G0-G1 arrest caused by inhibiting mTOR should antagonize cell death in S phase (or M) from inhibiting other PIKKs such as ATR (Johnson et al., 1999; King et al., 2015) . To better understand why Torin2 and its analogs are so effective, we developed two cell-cycle models based on discrete timestep Monte Carlo simulations. In these models, single cells progressed through G1, S, G2, and M ''compartments'' at rates matching experimental data. Following M phase, each mother cell was replaced by two G1 daughters. In the ''independence model,'' mTOR inhibition slowed transit only through G1, while in the ''interaction model,'' mTOR inhibition slowed transit through both G1 and S phase (Figures 6A and 6B) . In both models, ATR or Chk1 inhibition caused replication block and S-or M-phase lethality. GR values and total cell killing (''cell loss factor'') were then calculated for simulations with different degrees of mTOR and ATR or Chk1 inhibition.
When the rate of cell killing caused by ATR or Chk1 inhibition was low (between 0 and 0.15 in Figure 6C ), the independence model predicted greater cytostasis with increased mTOR inhibition. However, with higher cytotoxicity (values of 0.2 to 0.3), blocking mTOR had an antagonistic effect. A kinetic simulation of submaximal doses of an ATR or a Chk1 inhibitor combined with an mTOR inhibitor demonstrated only a modest effect on viable cell number ( Figure 6D ). In contrast, the interaction model predicted substantially decreased GR values and increased cell killing across a wide range of activities of ATR or Chk1 and mTOR inhibitors ( Figure 6E ). Antagonism between mTOR and ATR or Chk1 inhibitors was observed only at the highest levels of mTOR inhibition, which markedly prolonged G1. Kinetic simulations of submaximal drug activities acting in combination yielded growth curves with negative slopes, denoting cytotoxicity (Figure 6F) . Thus, the interaction model demonstrates that mTOR inhibitors causing an incomplete block at the G1-to-S phase transition can be beneficially combined with ATR or Chk1 inhibitors if the two drugs increase the probability of S-or M-phase cell killing. The cytotoxic effects of Torin2 and its analogs are thus likely to depend on the sensitivity of TNBC cells to inhibition of both mTOR and other PIKKs during S phase.
To test experimentally whether combinations of PI3K/AKT/ mTOR and ATR or Chk1 inhibitors are beneficial or antagonistic, we performed isobologram analysis on two-way dose-response landscapes for 16 different combinations-eight PI3K/AKT/ mTOR inhibitors versus an ATR or a Chk1 inhibitor-in five TNBC cell lines. Each of the 80 landscapes involved 100 different dose ratios. Using Loewe criteria (Tallarida, 2011), we classified combinations as exhibiting independence or favorable or antagonistic interactions ( Figure 6G ). In total, 46 out of 80 combinations exhibited pharmacological interaction, of which 45 (98%) were at least additive and only one was antagonistic (Figures 6H and S6A) . As predicted by modeling, favorable drug interactions gave rise to increased cell killing at submaximal concentrations of PI3K pathway inhibitors that only partly suppress mTOR signaling and incompletely block proliferation ( Figures 6I, S6B , and S6C). In HCC70 cells, for example, low doses of AZD8055 (0.03 3 GR max , 0.1 mM) were sufficient to delay progression of S phase; when combined with low doses of rabusertib (0.1 3 GR max , 0.32 mM), we observed significantly greater suppression of EdU incorporation in mid-and late S-phase cells compared to either drug alone ( Figures 6J and 6K) . Thus, as predicted by the interaction model, several PI3K pathway drugs can be combined with an ATR or a Chk1 inhibitor to produce a benefit in TNBC cell lines.
Low Doses of an mTOR Inhibitor and a Chk1 Inhibitor in Combination Cause Increased ssDNA in Mitotic Prophase and Death Exposure of HCC70 cells to low doses of AZD8055 and rabusertib in combination strongly suppressed DNA synthesis but did not cause the accumulation of S NR cells observed in other lines (i.e., HCC1806). We therefore asked whether low-dose combinations increase cell killing by a mechanism distinct from replication catastrophe, such as by causing cells with incompletely replicated DNA to inappropriately enter mitosis (King et al., 2015) . To investigate this possibility, we studied early mitotic (prophase) cells in asynchronous drug-treated cultures, as identified by positive staining for phospho-histone H3 (p-HH3) S10 and uncondensed chromatin (visualized by Hoechst staining).
To detect ssDNA, cells were labeled with BrdU for t = T d and stained with anti-BrdU antibodies under native conditions (Figure 7A) . We found that exposure of HCC70 cells to the combination of 0.03 3 GR max AZD8055 (0.1 mM) and 0.1 3 GR max rabusertib (0.32 mM) for t = 0.5 3 T d (24 h) produced higher fractions of BrdU-positive prophase cells and higher nuclear BrdU intensity levels than either drug alone or than a 0.3 3 GR max dose (1 mM) of Torin2 ( Figures 7B-7D) . Thus, the low-dose combination causes increased mitotic entry of HCC70 cells with ssDNA.
To determine the fates of these cells, we stained chromosomes, centromeres, spindle fibers, and centrosomes using Hoechst and anti-CREST, anti-b-tubulin, and anti-g-tubulin antibodies, following drug exposure for t = 0.5 3 T d (24 h). While AZD8055 alone decreased the total number of mitotic figures per high-powered field, rabusertib and the low-dose combination increased mitotic cell counts by 1.7-and 2.6-fold, respectively (n = 672 fields; p < 0.001 for combination versus rabusertib by one-way ANOVA and Tukey's test) ( Figure S7A ). The combination also increased the percentage of mitotic cells in metaphase to 80%, compared to 28% for DMSO, 36% for AZD8055 alone, and 58% for rabusertib alone (n = 569 mitotic cells; p < 0.01 for combination versus rabusertib) ( Figure S7B ). More than 90% of metaphase cells treated with AZD8055 plus rabusertib exhibited fragmented and/or misaligned chromosomes (n = 188 metaphase cells; p < 0.01 for combination versus rabusertib for severe misalignment and p < 0.05 for chromosome fragmentation) (Figures 7E and 7F) . Thus, cells with high levels of ssDNA are delayed in metaphase with incorrectly aligned or damaged chromosomes.
The interdependency of these events was made more obvious by time-lapse imaging of cells expressing H2B-GFP. Druginduced abnormalities in chromatin condensation visible in prophase frequently led to aberrant metaphases (n = 198 and 222 cells tracked through mitosis at 15 and 30 h, respectively) ( Figure 7G ). Mitotic death ensued after varying lengths of time without evidence of progression to anaphase. Although the rate of mitotic entry was lower in cells treated with the low-dose combination versus rabusertib alone (0.8% versus 1.7% of cells per hour after 30 h of drug exposure; Figure S7C ), nearly 80% of cells entering mitosis in the presence of the drug combination underwent mitotic catastrophe (a 2.2-fold increase over rabusertib alone) ( Figure 7H ). Of all drug-treated cells that died during mitosis, >97% failed between prophase and metaphase. We conclude that low doses of an mTOR inhibitor and a Chk1 inhibitor in combination can cause high rates of mitotic failure in some TNBC cell lines.
DISCUSSION
The frequency of mutations in PI3K pathway genes in human cancers has motivated development of numerous small-molecule kinase inhibitors (Janku et al., 2018) , few of which are effective in patients. We find that the preclinical compound Torin2 is unusually active in blocking proliferation and inducing death of PI3K-activated TNBC cells. In contrast, Torin2 is only partially cytostatic in non-transformed mammary epithelial cells. Torin2 was developed as an active-site mTOR inhibitor, but reconstitution experiments and analysis of chemical analogs both show that its activity in TNBC results from combined inhibition of mTOR and other PIKKs. In multiple TNBC lines, combinations of drugs targeting mTOR and ATR or Chk1 also show favorable effects. Thus, the polyselectivity of Torin2 is essential for its high activity in TNBC.
The benefits of combining mTOR and ATR or Chk1 inhibitors are unexpected because the two drug classes primarily affect successive cell-cycle stages. PI3K/AKT/mTOR signaling canonically regulates the G1-to-S phase transition (Liang and Slingerland, 2003) , while ATR-Chk1 is required during S phase and at the G2-M checkpoint (Zeman and Cimprich, 2014) . Prior studies have shown that combinations of chemotherapies or chemotherapy plus radiation are antagonistic when successive cell-cycle stages are affected (Johnson et al., 1999; Sui et al., 2004) . This is intuitive because cells blocked in G1 cannot proceed into later phases of the cell cycle where cytotoxicity occurs. However, in TNBC cells, we find that PI3K pathway drugs also disrupt progression of S phase. Modeling and experimentation together suggest that combinations of mTOR and ATR or Chk1 inhibitors can produce a benefit under conditions in which mTOR inhibition incompletely blocks cells in G1 and yet slows the rate of replication in S phase. Thus, the relative insensitivity of TNBC cells to the anti-proliferative effects of mTOR inhibitors at G1-S is a liability for monotherapy but an opportunity for combination therapies that exploit vulnerabilities in S phase. The strong effects of Torin2 on S-phase cells appear to result from a felicitous combination of reduced rates of DNA synthesis due to mTOR inhibition and reduced replication fork stability due to inhibition of additional PIKKs. The accumulation of ssDNA and DNA damage caused by exposure to Torin2 consequently results in the death of TNBC cells in S phase or subsequent mitosis.
We find that reduced rates of DNA synthesis following exposure to PI3K pathway inhibitors are associated with altered levels of nucleotides and their precursors. Short exposure of TNBC cells to mTOR inhibitors causes increased levels of cytidine and cytosine, which are known substrates for pyrimidine salvage pathways, as well as changes in the levels of dTDP and dTMP consistent with reduced activity of deoxythymidylate kinase, an enzyme required for pyrimidine synthesis. Prior studies have found that PI3K pathway activity promotes metabolic flux through the non-oxidative arm of the pentose phosphate pathway to generate ribose 5-phosphate and phosphoribosylpyrophosphate (PRPP), which are required for purine and pyrimidine synthesis (Juvekar et al., 2016; Wang et al., 2009 ). Moreover, mTORC1 regulates the activity of CAD, which catalyzes de novo pyrimidine synthesis, and expression of MTHFD2, which increases de novo purine biosynthesis (Ben-Sahra et al., 2013 , 2016 . In addition to causing metabolic derangements, mTOR inhibitors may also impede S-phase progression by reducing transcription and translation of proteins required for DNA replication and repair (Silvera et al., 2017) .
Dependencies on ATR-Chk1 signaling for S-phase progression are also likely to be multifactorial in origin (Zeman and Cimprich, 2014) . Oncogenes commonly amplified in TNBC such as MYC and CCNE1 cause excessive origin firing and conflicts between replication and transcription, resulting in stalled replication forks (Macheret and Halazonetis, 2018) . Because of the uncoupling of replicative helicases and DNA polymerases, stalled forks generate ssDNA and activate ATR-Chk1 signaling (Zeman and Cimprich, 2014) . In the presence of replication stress, ATR or Chk1 inhibition causes accumulation of ssDNA, consumption of replication factors, DNA damage, and ''replication catastrophe' ' (Toledo et al., 2013) . Loss-of-function mutations in TP53 may also contribute to this outcome, since absence of the DNA damage checkpoint in G1 renders cells more dependent on ATR-Chk1 signaling for the function of alternative cell-cycle checkpoints to maintain genomic integrity (Ma et al., 2011) . By inhibiting both mTOR and other PIKKs, Torin2 effectively exploits S-phase and checkpoint vulnerabilities in TNBC to promote tumor cell killing.
Translational Prospects
The foremost challenge in targeting the PI3K pathway for anti-cancer therapy is achieving anti-proliferative effects and cell killing sufficient to block tumor growth at doses tolerated by patients. The PI3K-mTOR inhibitor omipalisib is emblematic of this challenge: omipalisib produces substantial growth inhibition and apoptosis in TNBC cell lines, but the maximum tolerated dose in patients fails to fully inhibit intratumoral AKT and has only modest antitumor activity (Munster et al., 2016) . To improve the therapeutic index, recent efforts have focused on the development of selective inhibitors of PI3K p110 isoforms (a, b, d, and g), but these drugs often lack sufficient activity in solid tumors as monotherapy (Costa et al., 2015; Elkabets et al., 2013; Schwartz et al., 2015) . Thus, the polyselectivity of Torin2-like compounds appears promising in that it eliminates the requirement for strong inhibition of mitogenic signaling and G1 arrest to produce efficacy. We have also shown that certain PI3K pathway inhibitors can be used at relatively low doses in combination with other drugs to exploit replicative and/ or checkpoint vulnerabilities and produce cytotoxicity. Thus, new combinatorial strategies inspired by Torin2 may not only be more effective but also have a greater therapeutic index in patients.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
The media and culture conditions for all breast cancer and non-transformed mammary epithelial cell lines used in this study are described below. All cell lines were isolated from females, to the best of our knowledge. STR profiling was performed to confirm cell line identity. Cell Line Generation HCC70 H2B-GFP cells were established via lentiviral transduction (Addgene, 25999) followed by fluorescence-activated cell sorting (FACS) sorting for GFP-positive cells (Beronja et al., 2010) . HCC1806 cells expressing H2B-mTurquoise and mVenus-hGeminin (1-110) were established via sequential lentiviral transduction of CSII-pEF-H2B-mTurquoise and CSII-pEF-mVenus-geminin (1-110), followed by (FACS) for mTurquoise and mVenus double-positive cells (Sakaue-Sawano et al., 2008; Spencer et al., 2013) . The generation of Hs 578T NLS-mCherry and HCC1806 NLS-mCherry cell lines, which also express a F3aN400-Venus construct not utilized here, was previously described (Sampattavanich et al., 2018) . The media and culture conditions for genetically-engineered cell lines were identical to the parental cell lines.
METHOD DETAILS Western Blotting
To determine protein levels under unstimulated conditions, cells grown to approximately 75% confluency under the conditions described above were serum starved overnight and then lysed with Mammalian Protein Extraction buffer (M-PER; Thermo Scientific, 78501) supplemented with protease inhibitor cocktail (Sigma-Aldrich, P2714), 1mM sodium orthovanadate (Sigma-Aldrich, S6508), 5mM sodium pyrophosphate (Sigma-Aldrich, 221368), 50mM oxophenylarsine (EMD Biosciences, 521000) and 10mM bpV (phen) (EMD Biosciences, 203695). Two independent protein lysates were prepared from SK-BR-3 cells, and MDA-MB-231 cells were cultured in two different types of media (=total 48 samples for 46 different cell lines). Lysed cells were scraped off the plate, collected in microcentrifuge tubes and incubated on ice for 30min. Membranes and cell debris were sedimented by centrifugation at 20,000xg for 10min at 4 C. Supernatants were pooled, aliquoted and stored at À80 C. Protein concentration was determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific, 23225). Protein electrophoresis was performed using E-PAGE pre-cast 8% gels with 48 wells (Thermo Fisher Scientific, EP04808). Separated protein was transferred to Immobilon-FL PVDF membranes (EMD Millipore, IPFL00005) using the Criterion blotting system (Bio-Rad). Membranes were blocked for 1 h at room temperature (RT) with Odyssey blocking buffer (OBB; Li-COR 927-40000), incubated in primary antibodies in OBB overnight at 4 C, washed for 30min in PBS plus 0.1% Tween-20 (PBST), incubated in secondary antibody in OBB for 1 h at RT, and washed again for 30min in PBST. Anti-PTEN (Cell Signaling Technologies, 9188) and anti-INPP4B (Epitomics, 2512-1) primary antibodies were each used at 1:1000 dilution. Detection was performed using anti-rabbit IRDye 800CW pre-adsorbed secondary antibody (Rockland, 613-431-028) at 1:20,000 dilution. The fluorescence intensity of bands was quantified using the Odyssey system (Li-COR). 
Evaluation of Drug Sensitivity
All compounds except Torin2 analogs were obtained from MedChem Express. Stock solutions were prepared at a concentration of 10mM in DMSO and stored at -30 C. Torin2 analogs (QL-VIII-58, QL-V-107, QL-IV-100, QL-VI-86, QL-XII-47, QL-V-73, QL-X-138, QL-XII-108, QL-XII-61) were obtained from the laboratory of Nathanael Gray (Dana-Farber Cancer Institute) as 10mM stock solutions in DMSO. PI3K pathway drugs were arrayed in master library plates and pin-transferred to cells in Cell Carrier 384 well plates (PerkinElmer, 6007550). Torin2 analogs were delivered to cells in Cell Carrier 384 well plates using the D300 digital dispenser and accompanying software (Hewlett Packard). Cells were plated at a density of 1,000-2,000 cells per well using the Multidrop Combi (Thermo Scientific) and treatments were performed on the following day approximately 18-24h after plating. Inhibitors were administered at 9 different concentrations in at least technical triplicate and DMSO alone was used as a control. To determine cell number at the start (time = 0) and end (t = 72h) of treatment, cells were arrayed in two different plates with the time = 0 plate receiving no treatment and the 72h plate receiving DMSO control and active drug. Viable cells were identified using 15mL of staining solution, comprising 1:5,000 LIVE/DEAD Far Red Dead Cell Stain (Invitrogen, L10120), 1:10,000 Hoechst 33342 trihydrochloride trihydrate 10 mg/mL solution in water (Invitrogen, H3570) and 1:10 OptiPrep (Sigma-Aldrich, D1556) in PBS. Cells were incubated in staining solution for 30min at 37 C with 5% CO 2 and then fixed with 20mL fixing solution, comprising 1:20 37% formaldehyde (Sigma-Aldrich, F1635) and 1:5 OptiPrep in PBS, for 30min at RT. To achieve accurate cell counts, no aspiration of well contents was performed prior to fixing cells. Following fixation, all reagents were aspirated and replaced with 60mL of PBS using an EL406 Washer Dispenser (BioTek). Cells were imaged using the Operetta High-Content Imaging System (PerkinElmer). Six fields of view spanning each well in its entirety were acquired using the 10x high-NA objective lens and appropriate excitation/emission filters for Hoechst and LIVE/DEAD Far Red cell stains. The total viable cell count per well was determined using Columbus image analysis software (PerkinElmer), as described below.
Drug Dosing
When possible, GR max doses of drugs were used to facilitate a principled comparison of drug activities. However, for certain experiments, decreased drug doses were used due to excessive cell death or growth inhibition that resulted in insufficient cells for analysis (e.g. DNA synthesis in surviving cell fractions; EdU content in post-treatment S-phase fractions, etc.). For the F-ara-EdU data presented in Figure 1E , Torin2 and omipalisib were used at 0.3xGR max (1mM). For the signaling data presented in Figure 2A , Torin2 and omipalisib were used at 0.3xGR max (1mM) in HCC1806 cells. For the cell cycle data presented in Figure 2C , Torin2 and omipalisib were used at 0.3xGR max dose (BT-20: 1mM; HCC70: 0.32-1mM; HCC1806: 1mM). For the scatterplot data from HCC70 cells appearing in the middle and bottom rows of panels in Figure 2D , Torin2 and omipalisib were used at 0.1xGR max dose (0.1-0.32mM). For the analysis of EdU content presented in Figure 2E , drug doses for HCC70 and HCC1806 cells were as described for Figure 2C . For Hs 578T cells, Torin2 and omipalisib were used at 0.3xGR max dose (1mM). For BT-549 cells, AZD8055 was used at 0.3xGR max dose (0.32mM) and omipalisib and Torin2 were used at 0.03xGR max dose (0.1mM). For metabolomics profiling data presented in Figure 2F , GR max doses of rapamycin and AZD8055 were used (1mM) and compared to a 0.3xGR max dose of Torin2 (also 1mM).
Immunofluorescence Microscopy Cells were plated in Cell Carrier 384 well plates at either 1,000 (Hs 578T) or 2,000 (BT-20, BT-549, HCC1806, HCC38, HCC70) cells per well, treated with active drug or DMSO using the D300 digital dispenser, and fixed at various timepoints using 4% formaldehyde in PBS for 30min at RT. Cells were washed twice with PBS for 5min each at RT using the EL406 automated plate washer, permeabilized with 0.25% Triton X-100 (Bio-Rad, 1610407) in PBS for 15min, washed twice again for 5min each with PBS and blocked with OBB for at least 1h at RT. Cells were incubated with primary antibody diluted in OBB overnight at 4 C. The following morning, cells were washed three times with PBST for 5min each and then stained with secondary antibodies diluted 1:2,000 in OBB for 1h at RT. Secondary antibodies varied for different experiments but included Alexa Fluor 647 donkey anti-rabbit (Invitrogen, A31573), Alexa Fluor 647 donkey anti-mouse (Invitrogen, A31571), Alexa Fluor 647 goat anti-human (Invitrogen, A21445), Alexa Fluor 488 donkey anti-rabbit (Invitrogen, A21206), Alexa Fluor 488 goat anti-mouse (Invitrogen, A11001), and Alexa Fluor 568 goat anti-rabbit (Invitrogen, A11011). Cells were washed twice with PBST and once with PBS for 5min each prior to staining with Hoechst 33342 (Thermo Scientific, 1:10,000 in PBS) for 30min at RT. To facilitate segmentation of signal intensities specifically in the nucleus, cytoplasm, or whole cell in certain experiments, cells were simultaneously stained with 1:5000 Cellomics Whole Cell Stain (Thermo Scientific, 8403502) in PBS. Cells were washed twice with PBS, sealed with foil, and imaged using the Operetta High-Content Imaging System, the ImageXpress Micro Confocal High-Content Imaging System (Molecular Devices) or the IN Cell Analyzer 6000 (GE Healthcare Life Sciences) using the appropriate excitation and emission filters, depending on the specific assay.
Primary Antibodies and Dilutions
The following primary antibodies were obtained from Cell Signaling Technology (catalog number, dilution in OBB): rabbit anti-phospho-AKT T308 (13038, 1:400), rabbit anti-phospho-AKT S473 (4060, 1:200) , rabbit anti-phospho-Chk1 S317 (12302, 1:800), rabbit anti-phospho-Chk2 T68 (2661, 1:100), rabbit anti-phospho-4E-BP1 T37/46 (2855, 1:200) , rabbit anti-phospho-S6 S235/236 (4858, 1:1000), rabbit anti-phospho-H2A.X S139 (''gH2A.X'') (9718, 1:400), rabbit anti-phospho-histone H3 S10 (3377, 1:800), mouse anti-b-tubulin (86298, 1:400), rabbit anti-b-tubulin (2128, 1:400), mouse anti-BrdU (Bu20a) (5292, 1:200), rabbit anti-phospho-GSK3B S9 (5558, 1:400), rabbit anti-FOXO3 (2497, 1:200), rabbit anti-p21 (2947, 1:400), rabbit anti-p27 (3686, 1:400), and rabbit anti-phospho-Rb S807/811 (8516, 1:800). The following primary antibodies were obtained from Abcam (catalog number, dilution in OBB): rabbit anti-cyclin D1 (ab134175, 1:100), rabbit anti-geminin (ab195047, 1:100), and rabbit anti-cyclin A2 (ab181591, 1:500). Rabbit anti-phospho-RPA S4/8 antibodies were obtained from Bethyl (A300-245A, 1:400), rabbit anti-g-tubulin antibodies from Sigma (T5192, 1:400), and Human antibody against Centromere (CREST) antibodies from ImmunoVision (HCT-0100, 1:1000).
Single-Stranded DNA (ssDNA) and Cell-Cycle Analysis To measure ssDNA, newly-synthesized DNA in proliferating cells was first labeled with 10mM BrdU (Sigma, B9285) in growth media for a time equal to the measured cell line division time (T d ) in culture. Drug treatments were administered to labeled cells at T d using the D300 digital dispenser, and cells were fixed at various timepoints using 4% formaldehyde. BrdU was detected under non-denaturing (''native'') conditions by standard immunofluorescence microscopy, as described above. Cell-cycle analysis was performed after treating cells with active drug or DMSO-only control for time=T d , which was 28h for HCC1806 cells, 32h for Hs 578T cells, 40h for BT-549 cells, 45h for both HCC70 and HCC38 cells and 48h for BT-20 cells. Active S-phase cells were labeled with 10mM EdU (Thermo Fisher Scientific, C10637) in growth media for 0.025xT d in an incubator. Cells were then fixed with 4% formaldehyde in PBS for 30min at RT. Incorporated EdU was detected using the Click-iT EdU Plus Alexa Fluor 488 imaging kit (Thermo Fisher Scientific, C10637), per the manufacturer's instructions. Following the Click-iT reaction, cells were counterstained with 5mg/mL Hoechst dye and imaged using the Operetta or ImageXpress Micro Confocal High-Content Imaging System. In certain experiments, EdU-labeled cells were counterstained with anti-geminin, anti-cyclin A2, anti-phospho-pRb or anti-phospho-H2A.X antibodies overnight following the Click-iT reaction and prior to Hoechst staining. Continuous labeling of S-phase cells was performed using 1mM F-ara-EdU (Sigma, T511293) for 48 or 75h.
Live-Cell Microscopy
Time-lapse imaging of proliferation and apoptosis in live cells was performed using the Incucyte Zoom live-cell analysis system (Essen Bioscience) inside of an incubator maintained at 37 C and 5% CO 2 . Cells were plated at low density in 384-well plates (Corning, 3712) and images were taken of whole wells every 30-120min using the 43 lens. Drugs were administered during logarithmic-phase growth. For proliferation assays, stable cell lines with nuclear-expressing fluorophores (HCC70 H2B-GFP, Hs 578T NLS-mCherry, HCC1806 NLS-mCherry) were used to quantify live cell number at regular time intervals. Apoptotic cells were identified in wild-type cell lines using the Incucyte caspase-3/7 apoptosis assay reagent (Essen Bioscience, 4440), which was added to growth media at the recommended final concentration (5mM) several hours in advance of drug treatment. For each experimental replicate, the number of apoptotic cells was measured for each drug, dose, timepoint and cell line in technical triplicate.
For live-cell studies of mitosis, HCC70 H2B-GFP cells were plated at 2,000 cells per well in Cell Carrier 384-well plates. Plates were kept in a standard tissue culture incubator maintained at 37 C and 5% CO 2 for approximately 48h before cells were treated with drugs using the D300 digital dispenser. Starting at either 15 or 30h after drug treatment, cells were imaged every 5-10 minutes for 5-7h in a humidified chamber maintained at 37 C and 5% CO 2 using the 40x/0.95 NA lens of the IN Cell Analyzer 6000 microscope. The rate of mitotic entry and the percentage and stage of aberrations were visually scored for individual cells followed from prophase through cytokinesis in time-lapse image stacks.
To analyze the effects of drugs on cells in different stages of the cell cycle, HCC1806 cells expressing H2B-mTurquoise and mVenus-hGeminin were plated at 4,000 cells per well in 96-well plates (Ibidi, 89626) , kept in a standard tissue culture incubator overnight, treated with drugs the next morning using the D300 digital dispenser and then imaged every 12min for 48 h in a humidified chamber maintained at 37 C and 5% CO 2 using the 20x/0.75NA lens of the ImageXpress Micro high-content imaging system with binning 2x2. To minimize the effect of phototoxicity, cells were imaged at minimal laser intensity and exposure times necessary to achieve approximately 8-fold actual signal intensity versus background for each fluorophore. At the end of the experiment, cells were stained with Hoechst and LIVE/DEAD stain to identify and quantify viable cells. To assess for possible phototoxicity, cell counts for DMSO-only control wells on the same plate that did not undergo imaging were compared to cell counts for DMSO-only control wells that underwent time-lapse imaging. To validate environmental conditions such as temperature, humidity, and CO 2 , viable cells in an identically-treated plate kept in a standard tissue culture incubator set at 37 C and 5% CO 2 for 48 h (i.e., the duration of the experiment) were also compared by Hoechst and LIVE/DEAD co-staining.
Extraction of Polar Metabolites
Measurement of intracellular polar metabolite levels was performed to detect drug-induced changes in metabolic activity including de novo nucleotide biosynthesis and salvage pathways. BT-549 cells were selected for profiling following short drug exposure (i.e., 6 h) because inhibition of DNA synthesis was observed in S-phase cells (i.e., decreased EdU incorporation) prior to any detectable changes in cell cycle distribution, which can strongly bias metabolite levels. Cells in complete media were plated in 10 cm 2 dishes at 2.5x10 6 cells per dish and cultured at 37 C and 5% CO 2 . Approximately two days later when cells were 75-80% confluent, the media was replaced with 10mL of fresh media containing rapamycin, AZD8055 or Torin2, or an equivalent volume of DMSO. After 6h of treatment, the 10cm 2 dishes were placed on dry ice and the media was aspirated and replaced with ice cold 80% (v/v) methanol.
Dishes were kept at -80 C for 20min prior to using a cell scraper to produce a cell lysate/methanol mixture. The mixture for each sample was collected in a 15mL Eppendorf tube and cellular debris and protein were pelleted by centrifugation at 1,800xg for 5min at 4 C. The methanol supernatant containing polar metabolites was transferred to a new 15mL tube on dry ice and the cell debris/protein pellets were resuspended two additional times with methanol, centrifuged and re-pelleted. Recovered methanol supernatants for
Isobolograms and Analysis of Drug Interactions
Viable cell counts were determined after exposure to PI3K pathway and ATR or Chk1 inhibitors administered in combinations over two-dimensional gradients. Dose ranges typically spanned at least one order of magnitude and were selected based on the GR 50 values for each single agent. Continuous interpolations were constructed over the 2D response surface, which were then plotted as contour maps that highlight contours of equal inhibitory effect, or isoboles (Interpolation function and ContourPlot functions in Mathematica v11). As described by the Loewe additivity model, drug combinations were classified as additive or better based on the concept of dose equivalence, which manifests as diagonal isoboles that intersect both axes. Combinations were classified as antagonistic when isoboles were observed to deviate away from either axis, indicating that the drugs used together were less effective than either drug used alone. Combinations were classified as having no interaction when the activity of each drug appeared to be unaffected by the second drug, indicating independent action and manifested by linear isoboles. Examples of each case are shown in Figure 6G .
Cell-Cycle Model and Simulation of Combinatorial Drug Effect
The effects of mTOR and ATR or Chk1 inhibition individually or in combination were simulated by a discrete time-step Monte Carlo simulation. This simulation followed the progress of individual cells through the G1, S, G2, and M phases of the cell cycle, with each cell possessing a cell-state variable that increments with cell cycle progression. When a cell completed M phase, the mother cell was replaced by two daughter cells at the start of G1. Simulations were initialized with a population of 300 cells distributed throughout the cell cycle (i.e., asynchronous) based on experimentally measured cell cycle distributions for TNBC. mTOR inhibition slowed each cell's progress through G1 (independence model) or through both G1 and S phases (interaction model) by imposing a lower probability per time-step that the cell-state variable will increase. ATR or Chk1 inhibition imposed on each S-phase cell a specific rate of lethal replication block at each time-step. In light of prior knowledge that the effects of ATR or Chk1 inhibition during replication can ultimately cause death of cells in S phase (replication catastrophe) or in mitosis (mitotic catastrophe), simulations did not discriminate between whether the moment of death arises in S phase or in mitosis. In the interaction model, slowing of cells through S phase by mTOR inhibition was found to elicit an increase in the accumulated probability of lethal damage caused by ATR or Chk1 inhibition.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details regarding the number of experimental replicates, specific statistical tests used and the level of significance are described in the primary and supplementary figure legends. Significant differences are also indicated on the primary and supplemental figures.
Viable Cell Counts
Images of TNBC cells co-stained with Hoechst and LIVE/DEAD stains were analyzed using Columbus image data storage and analysis system (PerkinElmer) in order to quantify the total number of viable cells per well. Nuclear segmentation was performed using the Hoechst fluorescence intensity. For example, the number of HCC1806 cell nuclei in a particular well was determined using the following segmentation routine: module: 'Find Nuclei'; Channel: 'Hoechst'; Method: M; diameter 28mm; splitting coefficient: 0.45; common threshold: 0.05. Because of differences in nuclear size and morphology, optimal segmentation routines varied for each TNBC cell line and were determined in an empirical fashion. After identification of all nuclei in a well, additional features were extracted from images to exclude over/under segmented nuclei, doublets and non-viable cells from the total cell counts. Over/under segmented nuclei and doublets were of atypical size and shape compared to appropriately segmented nuclei. Non-viable cells were characterized by positive LIVE/DEAD staining and/or small pyknotic nuclei with extremely bright Hoechst signal. Collectively, the image analysis features that best identified these characteristics included nuclear area and roundness (module: 'Calculate Morphology Properties'); nuclear Hoechst intensity (module: 'Calculate Intensity Properties'); nuclear LIVE/DEAD stain intensity (module: 'Calculate Intensity Properties'); Hoechst texture features (module: 'Calculate Texture Properties'; SER Features, spot; scale: 4px; normalization by: unnormalized); and LIVE/DEAD texture features (module: 'Calculate Texture Properties'; SER Features; scale: 6px; normalization by: kernel). These extracted features were then used to set filters (i.e., gates) in the module 'Select Population.' In order to exclude extreme outliers representing non-viable or incorrectly segmented cells, filter settings were tuned interactively for each experimental replicate by visually comparing images of cells in DMSO-treated wells against images of cells in active drugtreated wells, and by using histograms produced by Columbus to visualize gates applied to the distribution of measured/calculated values for each feature. Identical gates were applied to all wells on each imaged plate.
Normalized Growth Rate Inhibition (GR) Metrics
Viable cell counts at time=0 and time=72hrs as determined in Columbus were then exported and used to compute GR values and GR metrics with the freely available online GR calculator (http://www.grcalculator.org/grcalculator/), which is based on previously published methods (Hafner et al., 2016) . Dose response curves of GR values were produced using MATLAB (MathWorks).
Quantification of Immunofluorescence Images
Immunofluorescence intensities in the entire cell or relevant subcellular compartment were measured in Columbus. Masks for the nucleus, cytoplasm and entire cell were generated by thresholding the Hoechst and the Whole Cell Stain channels. Custom masks were generated for each cell line due to variation in cell morphology. To quantify changes in the levels of proteins/phosphoproteins after treatment with DMSO or active drug, the relevant mask (as determined both by prior knowledge and by the observed staining pattern for each antibody) was applied to microscopy images and the fluorescence intensity was measured in that specific region of each cell. Levels of phospho-AKT (T308 and S473), phospho-4E-BP1 and phospho-GSK-3b in single cells were measured using a whole-cell mask. Phospho-S6 levels were measured using a cytoplasmic mask. Signals for BrdU, EdU, F-ara-EdU, cyclin A2, cyclin D1, FoxO3, geminin, p21, p27, p-Chk1, p-Chk2, p-H2A.X, p-histone H3, p-pRb and p-RPA levels were measured using a nuclear mask. For generation of PI3K signaling heatmaps, background-subtracted fluorescence intensity measurements were first normalized to values for DMSO. The PI3K signaling index was computed by adding the mean DMSO-normalized values of each of nine different proteins/phosphoproteins (scale 0-9, with 9 indicating no difference from DMSO). For signals that increase with PI3K pathway suppression (nuclear FOXO3, nuclear p21, and nuclear p27), the inverse value was used when computing the index. ''Percent high'' for any measured protein/post-translational modification was determined by applying an identical threshold to the entire distribution of values determined for cells treated with DMSO or active drug (see Figure 4A ). Total DNA content and EdU content per nucleus were calculated by multiplying the average nuclear fluorescence intensity by the nuclear area. All raw data were exported from Columbus; visualization, plotting and statistical analysis of the data were performed in MATLAB. Specific gating strategies are illustrated in individual figure panels; experimental replicates and statistical analyses are described in figure legends. Cells with mitotic aberrations were quantified based on visual inspection of individual microscopy images.
Cell-Cycle Analysis and Cell-Cycle-Stage-Specific Immunofluorescence Values After using Columbus to apply a nuclear mask to individual cells, average Hoechst and EdU intensity values were extracted and multiplied by the nuclear area to determine the DNA content and EdU content, respectively, on a single-cell level basis. The twoparameter plot of nuclear DNA content versus EdU content readily separated cells into three groups representing G1, S and G2/ M cells (see Figure S3A ). S-phase-non-replicating (S NR ) cells were identified based on DNA content intermediate to G1 and G2/M and no EdU signal. The percentages of cells in different cell cycle stages were determined in MATLAB by gating different groups of cells by DNA content (X) and EdU content (Y). In each experiment, specific values for gates were first determined by using data for cells treated with DMSO only and then applied to data for drug-treated cells. For analysis of immunofluorescence intensities in specific subpopulations of cells defined by cell cycle stage (e.g., Figure 2D ), nuclear intensity values from cells labeled with Hoechst/EdU and immunostained for a nuclear marker of interest were first plotted in MATLAB using the 3-way scatterplot function to preserve relationships among the three measured intensity values in single cells. Cells in different cell cycle stages were then gated as described above. The entire distribution of immunofluorescence intensity values for cells in each cell cycle stage was then replotted in relation to DNA content.
Live-Cell Analysis of Proliferation and Apoptosis
To determine population growth trajectories, total cell number in an entire well imaged using the 43 lens was determined using Incucyte Zoom software (Essen Bioscience). Cell number was calculated by identifying nuclei positive for GFP (HCC70) or mCherry (Hs 578T, HCC1806) in microscopy images, based on a background-subtracted fluorescence intensity threshold. C3/7-positive cells were similarly identified based on a fluorescence intensity threshold in the GFP channel. For each of three technical replicates in each independent experiment, C3/7 counts over time were plotted and area under the curve (AUC) calculations were determined in MATLAB and averaged. The mean fold-change value was then calculated as the ratio of the average AUC for drug versus the average for DMSO. Plotted mean fold-change and standard error values were determined using data from independent experiments.
Live-Cell Analysis of Drug Effect on the Cell Cycle Semi-automated tracking of individual HCC1806 cells expressing H2B-mTurquoise and mVenus-hGeminin(1-110) was performed using p53CinemaManual 2.0, a MATLAB-based software package freely available at: https://github.com/balvahal/p53CinemaManual/ releases/tag/v2.0.0. Individual cells were tracked in time-lapse movies using nuclear mTurquoise; mVenus fluorescence intensities were then extracted from each tracked cell nucleus. Cell cycle analysis was performed by analyzing plots of mVenus intensity versus time (see annotated trace of a representative single cell in DMSO, Figure 3A) . Each individual trace was manually reviewed and compared to DMSO control to ascertain the timing of cell cycle stage transitions. Data for each cell and each condition were then compiled into matrices, which were used to generate heatmaps. Cell divisions were scored by direct visualization of chromosome segregation followed by appearance of daughter cell nuclei. Cell deaths were scored by the appearance of nuclear fragmentation (karyorrhexis).
Analysis of Steady-State Polar Metabolites
Metabolite peak intensities for drug-treated samples were compared to peak intensities for samples treated with DMSO (N=3 independent experiments) using MetaboAnalyst 4.0 (MA) (https://www.metaboanalyst.ca/MetaboAnalyst/faces/home.xhtml). Prior to uploading the data, an initial processing step was performed to exclude metabolites with two or more missing values in either the DMSO or active treatment group. For rapamycin, AZD8055, and Torin2, 34 (11.2%), 35 (11.6%), and 34 (11.2%) of 303 metabolites, respectively, were excluded for this reason. For a small number of excluded metabolites (4/34 for rapamycin, 8/35 for AZD8055, and 9/34 for Torin2), three numerical values were available for DMSO but only 0 or 1 for active treatment, suggesting that treated samples had undetectable levels by mass spectrometry due to low abundance. Because the fold-change values for these metabolites were incalculable but in certain cases could be large, these metabolites and their raw values are listed in separate tables in Table S4 . To facilitate downstream analysis in MA, single missing values in either treatment group were imputed by taking the average of the two measured values. This step was performed prior to analyzing the data in MA because the software performs missing value estimation for each metabolite using all of the sample data rather than the data for individual treatment groups. In certain instances, this method was observed to obscure strong changes in metabolite levels induced by drug treatment. Once the data were uploaded to MA, no additional filtering was applied. Sample data were quantile-normalized, and then the metabolite data were log-transformed. No scaling was performed. The effects of data normalization and transformation were visualized using diagnostic plots. Fold-change values were calculated as the ratio between group means, using absolute values of metabolite data prior to log-transformation. T-tests were performed to assess the statistical significance of fold-change values. Volcano plots were generated using fold-change values and p-values from T-tests to identify metabolites with the largest and most significant changes after drug treatment.
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